Comparison · NCT05256017-5cc0ec90
Acoziborole vs Placebo: Occurrence of TEAEs - Nausea
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. Acoziborole vs Placebo: Occurrence of TEAEs - Nausea. Trial comparisons, record NCT05256017-5cc0ec90. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT05256017-5cc0ec90
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.00773 | 0.00375 | 0.0159 | wilson | |
| Risk in group 2 | 0.01 | 0.00341 | 0.029 | wilson | |
| Risk difference, group 1 minus group 2 | -0.00227 | -0.0217 | 0.0082 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 0.773 | 0.201 | 2.97 | log | |
| Odds ratio, group 1 over group 2 | 0.771 | 0.198 | 3 | log | |
| Number needed to treat, for one fewer participant with the outcome on Acoziborole than on Placebo | 440 | from the risk difference interval | the interval includes no difference |
Source ClinicalTrials.gov
Groups2
Group 2 names the comparator: placebo.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | Acoziborole | Acoziborole: 3 tablets of 320 mg | 7 | 906 | OG000 |
| Group 2 | Placebo | Acoziborole matching placebo: 3 tablets of 320 mg | 3 | 300 | OG001 |
Source ClinicalTrials.gov
Outcome
- Type
- PRIMARY
- Title
- Occurrence of TEAEs - Nausea
- Description
- Occurrence and excess rate (95% CI) of common TEAEs (by PT, for PTs reported in ≥1% of participants in either arm).
- Time frame
- From the investigational product administration (Day 1) to the Month 4 follow-up visit (End of Study).
- Population
- Safety set: participants who received at least 1 tablet of the investigational product (based on the actual treatment received, confirmed by drug concentration data).
Source ClinicalTrials.gov
Trial
- Title
- Safety and Tolerability Study of Acoziborole in g-HAT Seropositive Subjects
- NCT number
- NCT05256017
- Phases
- PHASE2, PHASE3
- Conditions
- Trypanosomiasis, African, Trypanosoma Brucei Gambiense; Infection, Sleeping Sickness
- Interventions
- Acoziborole, Placebo
- Lead sponsor
- Drugs for Neglected Diseases
- Results first posted
- 2025-03-20
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT05256017?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT05256017-5cc0ec90